Baker Bros. Advisors’s Spyre Therapeutics SYRE Stock Holding History

Baker Bros. Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$50.4M	Hold	1,000,000	–	–	0.29%	36
2025 Q4	$32.8M	Hold	1,000,000	–	–	0.19%	41
2025 Q3	$16.8M	Buy	1,000,000 +373,297	+60%	+$6.09M	0.12%	50
2025 Q2	$9.38M	Buy	+626,703	New	+$9.27M	0.09%	54
2023 Q3	–	Sell	-136,404	Closed	-$1.54M	–	108
2023 Q2	$1.54M	Hold	136,404	–	–	0.01%	100
2023 Q1	$989K	Hold	136,404	–	–	0.01%	99
2022 Q4	$1.53M	Hold	136,404	–	–	0.01%	101
2022 Q3	$1.79M	Hold	136,404	–	–	0.01%	101
2022 Q2	$1.72M	Hold	136,404	–	–	0.01%	98
2022 Q1	$7.84M	Hold	136,404	–	–	0.05%	71
2021 Q4	$16.2M	Hold	136,404	–	–	0.08%	62
2021 Q3	$27.1M	Hold	136,404	–	–	0.12%	54
2021 Q2	$23.7M	Hold	136,404	–	–	0.1%	62
2021 Q1	$27M	Hold	136,404	–	–	0.12%	56
2020 Q4	$26.8M	Sell	136,404 -38,780	-22%	-$8.04M	0.1%	51
2020 Q3	$31.1M	Hold	175,184	–	–	0.12%	42
2020 Q2	$40.5M	Buy	175,184 +106,640	+156%	+$20.3M	0.18%	36
2020 Q1	$7.99M	Hold	68,544	–	–	0.05%	54
2019 Q4	$13.1M	Hold	68,544	–	–	0.07%	51
2019 Q3	$13.2M	Hold	68,544	–	–	0.09%	49
2019 Q2	$11.7M	Hold	68,544	–	–	0.08%	49
2019 Q1	$13.8M	Hold	68,544	–	–	0.09%	43
2018 Q4	$12.8M	Buy	68,544 +13,029	+23%	+$2.76M	0.11%	45
2018 Q3	$13.3M	Hold	55,515	–	–	0.09%	49
2018 Q2	$14.7M	Buy	55,515 +10,000	+22%	+$2.46M	0.11%	51
2018 Q1	$11.3M	Hold	45,515	–	–	0.1%	54
2017 Q4	$6.16M	Hold	45,515	–	–	0.05%	71
2017 Q3	$5.61M	Hold	45,515	–	–	0.05%	74
2017 Q2	$4.38M	Buy	45,515 +37,916	+499%	+$5.24M	0.04%	66
2017 Q1	$1.42M	Sell	7,599 -8,570	-53%	-$1.21M	0.01%	94
2016 Q4	$1.76M	Hold	16,169	–	–	0.02%	94
2016 Q3	$2.59M	Hold	16,169	–	–	0.02%	87
2016 Q2	$1.97M	Buy	+16,169	New	+$3.1M	0.02%	98

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Baker Bros. Advisors's SYRE Position: Q1 2026 in Review

Baker Bros. Advisors held its Spyre Therapeutics (SYRE) position steady in Q1 2026 at 1,000,000 shares worth $50.4M. The position accounts for 0.29% of the portfolio, ranked #36.

Baker Bros. Advisors first reported a position in SYRE in Q2 2016 and has held it in 33 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

Baker Bros. Advisors held 1,000,000 shares of Spyre Therapeutics worth $50.4M as of Q1 2026.
Baker Bros. Advisors left its Spyre Therapeutics share count unchanged in Q1 2026.
Spyre Therapeutics made up 0.29% of Baker Bros. Advisors's portfolio in Q1 2026, its #36 holding.
Baker Bros. Advisors first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 33 quarters since.
197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.